Literature DB >> 16822578

LKB1 mutation in large cell carcinoma of the lung.

Diansheng Zhong1, Lizheng Guo, Itziar de Aguirre, Xiuju Liu, Neil Lamb, Shi-Yong Sun, Anthony A Gal, Paula M Vertino, Wei Zhou.   

Abstract

Germline inactivation of LKB1 is responsible for Peutz-Jeghers syndrome, an autosomal dominant disorder characterized by benign hamartomas of the GI tract and an increased predisposition to certain cancers, including lung. Acquired mutations in LKB1 are rarely observed in most sporadic tumor types except for adenocarcinomas of the lung where up to 50% harbor inactivating mutations. In this study, we focused on LKB1 mutations in lung cancer cell lines originating from large cell carcinomas. We identified a novel 1.5kb interstitial deletion within LKB1 gene in H157 cancer cells. Homozygosity mapping-of-deletion analysis (HOMOD) analysis showed that the deletion is accompanied by LOH of one parental allele, indicating biallelic inactivation of LKB1. This deletion results in an LKB1 transcript lacking exons 2 and 3 and a predicted in-frame deletion of 58 amino acids within the kinase domain of the LKB1 protein. The truncated transcript was expressed at relatively low levels, and the truncated LKB1 protein was virtually undetectable in this cell line. To determine the impact of LKB1 protein truncation on its function, we examined AMPK-alpha, a downstream target of LKB1 kinase activity triggered by low energy stress conditions. Phosphorylation of AMPK-alpha was attenuated in H157 cells treated with 2-deoxyglucose, and could be rescued by expression of an exogenous GFP-LKB1 fusion protein. Therefore, our data suggest that LKB1 function is compromised in H157. Of the four cell lines and six primary tumors of large cell lung carcinoma origin that have been evaluated in this and other studies, LKB1 mutations have been found in three cases. These results suggest that, in addition to adenocarcinomas, acquired loss of function mutations in LKB1 may also be frequently involved in the pathogenesis of large cell lung carcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822578     DOI: 10.1016/j.lungcan.2006.05.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  32 in total

1.  STE20-related kinase adaptor protein α (STRADα) regulates cell polarity and invasion through PAK1 signaling in LKB1-null cells.

Authors:  Carrie M Eggers; Erik R Kline; Diansheng Zhong; Wei Zhou; Adam I Marcus
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

2.  Metformin impairs the growth of liver kinase B1-intact cervical cancer cells.

Authors:  Xuxian Xiao; Qiongqiong He; Changming Lu; Kaitlin D Werle; Rui-Xun Zhao; Jianfeng Chen; Ben C Davis; Rutao Cui; Jiyong Liang; Zhi-Xiang Xu
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

3.  A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer.

Authors:  E-J Choi; B-J Jung; S-H Lee; H-S Yoo; E-A Shin; H-J Ko; S Chang; S-Y Kim; S-M Jeon
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

Review 4.  Targeting the LKB1 tumor suppressor.

Authors:  Rui-Xun Zhao; Zhi-Xiang Xu
Journal:  Curr Drug Targets       Date:  2014-01       Impact factor: 3.465

Review 5.  TIF-IA: An oncogenic target of pre-ribosomal RNA synthesis.

Authors:  Rui Jin; Wei Zhou
Journal:  Biochim Biophys Acta       Date:  2016-09-15

Review 6.  Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers.

Authors:  Jennifer L Herrmann; Yevgeniya Byekova; Craig A Elmets; Mohammad Athar
Journal:  Cancer Lett       Date:  2011-03-29       Impact factor: 8.679

7.  Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.

Authors:  Kaisheng Mao; Fakeng Liu; Xiuju Liu; Fadlo R Khuri; Adam I Marcus; Mingsong Li; Wei Zhou
Journal:  Lung Cancer       Date:  2015-03-01       Impact factor: 5.705

8.  Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells.

Authors:  Lizheng Guo; Diansheng Zhong; Stephen Lau; Xiuju Liu; Xue-Yuan Dong; Xiaodong Sun; Vincent W Yang; Paula M Vertino; Carlos S Moreno; Vijay Varma; Jin-Tang Dong; Wei Zhou
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

9.  Molecular dissection of AKT activation in lung cancer cell lines.

Authors:  Yanan Guo; Jinyan Du; David J Kwiatkowski
Journal:  Mol Cancer Res       Date:  2013-01-14       Impact factor: 5.852

10.  LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins.

Authors:  Diansheng Zhong; Xiuju Liu; Fadlo R Khuri; Shi-Yong Sun; Paula M Vertino; Wei Zhou
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.